Search Results

You are looking at 111 - 120 of 530 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Presenter: Jennifer J.D. Morrissette

generated and how to use them will be the most important aspect in getting the most out of genomic testing in treating your patients,” Jennifer J.D. Morrissette, PhD, Associate Professor, Department of Clinical Pathology and Laboratory Medicine, and

Full access

Vivek Subbiah and Kanishka Sircar

using a commercially available assay for mutational assessment of 5 diagnostic microsatellite sequences; a pathology specimen is noted as MSI-H if at least 2 of 5 microsatellites harbor mutations. NGS or immunohistochemistry for MMR proteins may be also

Full access

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

. Risk of recurrence is determined by tumor size, location, mitotic rate, and tumor rupture. Prediction tools, such as the modified NIH method, 8 the Armed Forces Institute of Pathology (AFIP; Miettinen criteria), 9 and the Memorial Sloan Kettering

Full access

Robert A. Swarm and Maria Dans

C, and HIV. In LMCs, late-stage presentation and inaccessible diagnosis and treatment are common. Only 26% of LMCs have available pathology service, and fewer than one-third have treatment services available in the public sector. Other barriers to

Full access

Jonathan M. Loree and Scott Kopetz

Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology [published online ahead of print February 6, 2017] . J Clin Oncol , doi: 10.1200/JCO.2016.71.9807 . 2

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

guidelines, at www.NCCN.org [ST-1]). 5 , 6 This revision differs from the 1997 edition of the AJCC staging by incorporating the increasing use of novel imaging and pathology techniques used at diagnosis (e.g., sentinel node biopsy and immunohistochemistry

Full access

Katherine Cotangco, Mary Meram, and M. Patrick Lowe

subsequently underwent a dilation and curettage. Pathology results suggested leiomyosarcoma. A CT scan of the chest, abdomen, and pelvis revealed a right uterine body peripherally enhancing partially calcified necrotic 5.8 × 5.0-cm mass, bilateral pulmonary

Full access

Jaffer A. Ajani

2013 ; 8 : 1558 – 1562 . 9. Taketa T Sudo K Correa AM . Post chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma . J Natl Compr Canc Netw , in press . 10

Full access

Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton

presence of bowel perforation or obstruction, specific systemic chemotherapy and targeted therapy agents, molecular pathology testing ( KRAS , BRAF , and microsatellite instability [MSI]), comorbidities, and hospital characteristics. Given the complex

Full access

Alexander S. Baras, Jarushka Naidoo, Christine L. Hann, Peter B. Illei, Charles W. Reninger III, and Josh Lauring

(45 U/L). Fiberoptic bronchoscopy was performed with fine-needle aspiration (FNA) of a station 7 lymph node, and the pathology was read as poorly differentiated squamous cell carcinoma (SCC) ( Figure 2 ). Immunostains were positive for p63 and negative